Transcription factor AP-1, and the role of fra-2

Immunology and Cell Biology

Volumn 74, Issue 2, 1996, Pages 121-133

  Foletta, Victoria C ^a  

^a Biology and Environment   (Australia)

Author keywords

Fos genes; Fos related antigens; Gene expression regulation; Immediate early genes; Jun genes; Transcription factor AP 1; Transcription factors

Indexed keywords

TRANSCRIPTION FACTOR AP 1;

GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029999866     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.17     Document Type: Review

References (163)

1. Darnell JE. Variety in the level of gene control in eukaryotic cells. Nature 1982; 297: 365-71.
2. Saltzman AG, Weinmann R. Promoter specificity and modulation of RNA polymerase II transcription. FASEB J. 1989; 3: 1723-33.
3. Somerville J. RNA polymerase I and cellular transcription factors. Nature 1984; 310: 189-90.
4. Chambon P. Eukaryotic nuclear RNA polymerases. Annu. Rev. Biochem. 1975; 44: 613-38.
5. Breathnach R, Chambon P. Organization and expression of eukaryotic split genes coding for proteins. Annu. Rev. Biochem. 1981; 50: 349-83.
6. Dynan WS, Tjian R. Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins. Nature 1985; 316: 774-7.
7. McKnight S, Tjian R. Transcriptional selectivity of viral genes in mammalian cells. Cell 1986; 46: 795-805.
8. McKnight SL, Kingsbury R. Transcriptional control signals of a eukaryotic protein-encoding gene. Science 1982; 217: 316-24.
9. Moreau P, Hen R, Wasylyk B, Everett R, Gaub MP, Chambon P. The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucl. Acids Res. 1981; 9: 6047-68.
10. Banerji J, Rusconi S, Schaffner W. Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. Cell 1981; 27: 299-308.
11. Maniatis T, Goodbourn S, Fischer JA. Regulation of inducible and tissue-specific gene expression. Science 1987; 236: 1237-45.
12. Wildeman AG, Zenke M, Schatz C et al. Specific protein binding to the simian virus 40 enhancer in vitro. Mol. Cell. Biol. 1986; 6: 2098-105.
13. Zenke M, Grundstrom T, Matthes H et al. Multiple sequence motifs are involved in SV40 enhancer function. EMBO J. 1986; 5: 387-97.
14. Nakajima N, Horikoshi M, Roeder RG. Factors involved in specific transcription by mammalian RNA polymerase II: Purification, genetic specificity, and TATA box promoter interactions of TFIID. Mol. Cell. Biol. 1988; 8: 4028-40.
15. Dynlacht BD, Hoey T, Tjian R. Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell 1991; 66: 563-76.
16. Conaway RC, Conaway JW. General initiation factors for RNA polymerase II. Annu. Rev. Biochem. 1993; 62: 161-90.
17. Zawel L, Reinberg D. Initiation of transcription by RNA polymerase II: A multi-step process. Prog. Nucl. Acid Res. Mol. Biol. 1993; 44: 67-108.
18. Buratowski S, Hahn S, Guarente L, Sharp PA. Five intermediate complexes in transcription initiation by RNA polymerase II. Cell 1989; 56: 549-61.
19. Koleske AJ, Young RA. An RNA polymerase II holo-enzyme responsive to activators. Nature 1994; 368: 466-9.
20. Gill G, Pascal E, Tseng ZH, Tjian R. A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc. Natl Acad. Sci. USA 1994; 91: 192-6.
21. Weinzierl RO, Dynlacht BD, Tjian R. Largest subunit of Drosophila transcription factor IID directs assembly of a complex containing TBP and a coactivator. Nature 1993; 362: 511-7.
22. Hoey T, Weinzierl RO, Gill G, Chen JL, Dynlacht BD. Tjian R. Molecular cloning and functional analysis of Drosophilia TAF110 reveal properties expected of coactivators. Cell 1993; 72: 247-60.
23. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu. Rev. Biochem. 1991; 60: 281-319.
24. Carroll SB, Scott MP, Localization of the fushi tarazu protein during Drosophila embryogenesis. Cell 1985; 43: 47-57.
25. Carroll SB, Winslow GM, Schupbach T, Scott MP. Maternal control of Drosophila segmentation gene expression. Nature 1986; 323: 278-80.
26. Gopal TV, Shimada T, Baur AW, Nienhuis AW. Contribution of promoter to tissue-specific expression of the mouse immunoglobulin kappa gene. Science 1985; 229: 1102-4.
27. Lau LF, Nathans D. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 1985; 4: 3145-51.
28. McMahon SB, Monroe JG. Role of primary response genes in generating cellular responses to growth factors. FASEB J. 1992; 6: 2707-15.
29. Lee W, Haslinger A, Karin M, Tjian R. Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature 1987; 325: 368-72.
30. Treisman R. Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5′ element and c-fos 3′ sequences. Cell 1985; 42: 889-902.
31. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell 1987; 51: 251-60.
32. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987; 49: 741-52.
33. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem. Biophys. Acta 1991; 1072: 129-57.
34. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987; 238: 1386-1392.
35. Rauscher FJ III, Cohen DR, Curran T et al. Fos-associated protein p39 is the product of the jun proto-oncogene. Science 1988; 240: 1010-6.
36. Franza BR Jr, Rauscher FJ III, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science 1988; 239: 1150-3.
37. Landshultz WH, Johnson PF, McKnight SL. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 1988; 240: 1759-64.
38. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl Acad. Sci. USA 1987; 84: 2848-52.
39. Vogt PK, Bos TJ, Doolittle RF. Homology between the DNA-binding of the GCN4 regulatory protein of yeast and the carboxy terminal region of a protein coded for by the oncogene jun. Proc. Natl Acad Sci. 1987; 84: 3316-19.
40. Ryder K, Lau L, Nathans D. A gene activated by growth factors is related to the oncogene v-jun. Proc. Natl Acad. Sci. USA 1988; 85: 1487-91.
41. Schutte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. junB inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell 1989; 59: 987-97.
42. Hirai SI, Ryseck RP, Mechta F, Bravo R, Yaniv M. Characterization of junD: A new member of the jun protooncogene family. EMBO J. 1989; 8: 1433-9.
43. Ryder K, Lanahan A, Perez-Albeurne E, Nathans D. Jun D: A third member of the jun gene family. Proc. Natl Acad Sci. USA 1989; 86: 1500-3.
44. Nakabeppu Y, Ryder K, Nathans D. DNA binding activities of three murine Jun proteins: Stimulation by Fos. Cell 1988; 55: 907-15.
45. Halazonetis T, Georgopoulos K, Greenberg M, Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 1988; 55: 917-24.
46. Cohen DR, Ferreira CP, Gentz R, Franza BR Jr, Curran T. The product of a fos-related gene, fra-1, binds cooperatively to the AP-1 site with Jun: Transcription factor AP-1 is comprised of multiple protein complexes. Gen. Dev. 1989; 3: 173-84.
47. Suzuki T, Okuno H, Yoshida T, Endo T, Nishina H, Iba H. Difference in transcriptional regulatory function between c-Fos and Fra-2. Nucl. Acids Res. 1991; 19: 5537-42.
48. Zerial M, Toschi L, Ryseck R-P, Schuermann M, Muller R, Bravo R. The product of a novel growth factor activated gene, FosB, interacts with Jun proteins enhancing their DNA binding activity. EMBO J. 1989; 8: 805-13.
49. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene Jun/AP-1 by serum and TPA. Nature 1988; 334: 629-31.
50. Finkel MP, Biskis BO. Virus induction of osteosarcoma in mice. Science 1966; 151: 698-701.
51. Finkel MP, Biskis BO. Experimental induction of osteosarcomas. Prog. Exp. Tumor Res. 1968; 10: 72-111.
52. Curran T, Gordon MB, Rubino KL, Sambucetti LC. Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro. Oncogene 1987; 2: 79-84.
53. Molders H, Jenuwein T, Adamkiewicz J, Muller R. Isolation and structural analysis of a biologically active chicken c-fos cDNA: Identification of evolutionarily conserved domains in fos protein. Oncogene 1987; 1: 377-85.
54. Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T, Karin M. The c-fos protein interacts with Jun/AP-1 to stimulate transcription of AP-1 responsive gene. Cell 1988; 54: 541-52.
55. Sassone-Corsi P, Sisson JC, Verma IM. Transcriptional autoregulation of the proto-oncogene fos. Nature 1988; 334: 314-9.
56. Nakabeppu Y, Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991; 64: 751-9.
57. Cohen DR, Curran T. fra-1: A serum-inducible, cellular immediate-early gene that encodes a Fos-related antigen. Mol. Cell. Biol. 1988; 8: 2063-9.
58. Matsui M, Tokuhara M, Konuma Y, Nomura N, Ishizaki R. Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene 1990; 5: 249-55.
59. Nishina H, Sato H, Suzuki T, Sato M, Iba H. Isolation and characterisation of fra-2, an additional member of the fox gene family. Proc. Natl Acad. Sci. USA 1990; 87: 3619-23.
60. Manounas M, Ross S, Luong C et al. Analysis of the genes involved in the insulin transmembrane mitogenic signal in Chinese hamster ovary cells. CHO-K1, utilizing insulin-independent mutants. Proc. Natl Acad. Sci. USA 1991; 88: 3530-4.
61. Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 1984; 311: 433-7.
62. Muller R, Bravo R, Burckhardt J, Curran T. Induction of c-fos gene and protein growth factors precedes activation of c-myc. Nature 1984; 312: 716-20.
63. Yoshida T, Sato H, Iba H. Transcription of fra-2 mRNA and phosphorylation of Fra-2 protein are stimulated by serum. Biochem. Biophys. Res. Commun. 1991; 174: 934-9.
64. Miller AD, Curran T, Verma IM. c-fos protein can induce cellular transformation: A novel mechanism of activation of a cellular oncogene. Cell 1984; 36: 51-60.
65. Holt JT, Gopal TV, Moulton AD, Nienhuis AW. Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc. Natl Acad. Sci. USA 1986; 83: 4794-8.
66. Riabowol KT, Vosatka RJ, Ziff EB, Lamb NJ, Feramisco JR. Microinjection of fos-specific antibodies blocks DNA synthesis in fibroblast cells. Mol. Cell. Biol. 1988; 8: 1670-6.
67. 1 transition in mouse fibroblasts. Mol. Cell. Biol. 1991; 9: 4466-72.
68. 1 transition and during exponential growth in mouse fibroblasts: Differential role of Fos proteins. Mol. Cell. Biol. 1992; 12: 5015-23.
69. Treisman R. The serum response element. Trends Biochem. Sci. 1992; 17: 423-6.
70. Treisman R. Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J. 1987; 6: 2711-17.
71. Herrera RE, Shaw PE, Nordheim A. Occupation of the c-fos serum response element in vivo by a multi-protein complex is unaltered by growth factor induction. Nature 1989; 340: 68-70.
72. Shaw PE, Schroter H, Nordheim A. The ability of a ternary complex to form over the serum response element correlates with serum inducibility of the human c-fos promoter. Cell 1989; 56: 563-72.
73. TCF. Nature 1991; 354: 531-4.
74. Dalton S, Marais R, Wynne J, Treisman R. Isolation and characterization of SRF accessory proteins. Philos. Trans. R. Soc. Soc. Lond. B. Biol. Sci. 1993; 340: 325-32.
75. Zinck R, Hipskind RA, Pingoud V, Nordheim A. c-fos transcriptional activation and repression correlate temporally with the phosphorylation status of TCF. EMBO J. 1993; 12: 2377-87.
76. Hipskind RA, Baccarini M, Nordheim A. Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo. Mol. Cell. Biol. 1994; 14: 6219-31.
77. Karin M. Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr. Opin. Cell. Biol. 1994; 6: 415-24.
78. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993; 73: 381-93.
79. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258: 478-80.
80. Kyriakis S, App H, Zhung X et al. Raf-1 activates MAP kinase kinase. Nature 1992; 358: 417-21.
81. Vojtek AB, Hollenberg SM, Cooper JA. Mammalian ras interacts directly with the serine/threonine kinase raf. Cell 1993; 74: 205-14.
82. α activates Raf-1 by direct phosphorylation. Nature 1993; 364: 249-52.
83. Metz R, Ziff E. cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to translocate to the nucleus and induce c-fos transcription. Genes Dev. 1991; 5: 1754-66.
84. Metz R, Ziff E. The helix-loop-helix protein rE12 and the C/EBP-related factor rNFIL-6 bind to neighboring sites within the c-fos serum response element. Oncogene 1991; 6: 2165-78.
85. Grueneberg DA, Natesan S, Alexandre C, Gilman MZ. Human and Drosophila homeodomain proteins that enhance the DNA-binding activity of serum response factor. Science 1992; 257: 1089-95.
86. Gualoberto A, LePage D, Pons G et al. Functional antagonism between YY1 and the serum response factor. Mol. Cell. Biol. 1992; 12: 4209-14.
87. Attar RM, Gilman MZ. Expression of a novel zinc finger protein that binds to the serum response element. Mol. Cell Biol. 1992; 12: 2432-43.
88. Meyer DJ, Stephenson EW, Johnson L, Cochran B. The serum response element can mediate induction of c-fos by growth hormone. Proc. Natl Acad. Sci. USA 1993; 90: 6721-5.
89. Karagianni N, Tsawdarglou N. The c-fos response element (SRE) confers negative response to glucocorticoids. Oncogene 1994; 9: 2327-34.
90. Shaw PE, Frasch S, Nordheim A. Repression of c-fos is mediated through p67SRF bound to the SRE. EMBO J. 1989; 8: 2567-74.
91. Lucibello FC, Lowag C, Neuberg M, Muller R. Transrepression of the mouse c-fos promoter: A novel mechanism of Fos-mediated trans-regulation. Cell 1989; 59: 999-1007.
92. Beelman CA, Parker R. Degradation of mRNA in eukaryotes. Cell 1995; 81: 179-83.
93. Chen C-YA, Chen T-M, Shyu A-B. Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function. Mol. Cell. Biol. 1994; 14: 416-26.
94. Chen C-YA, Shyu A-B. Selective degradation of early-response-gene mRNAs: functional analyses of sequence features of the AU-rich elements. Mol. Cell. Biol. 1994; 14: 8471-82.
95. Roux P, Blanchard J-M, Fernandez A, Lamb N, Jeanteur P. Piechaczyk M. Nuclear localization of c-Fos, but not v-Fos proteins, is controlled by extracellular signals. Cell 1990; 63: 341-51.
96. Boyle WJ et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991; 64; 573-84.
97. Chou S, Baichwal V, Ferrell JE Jr. Inhibition of c-Jun DNA-binding by mitogen-activated protein kinase. Mol. Cell. Biol. 1992; 3: 1117-30.
98. Lin A, Frost J, Deng T et al. Casein kinase II is a negative regulator of c-Jun DNA-binding and AP-1 activity. Cell 1992; 70: 777-89.
99. Smeal T, Binetruy B, Mercola D, Birrer M, Karin M. Phosphorylation of c-Jun on serines 63 and 73 is required for oncogenic and transcriptional cooperation with Ha-Ras. Nature 1991; 354: 494-6.
100. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that bind and potentiate the c-Jun activation domain. Genes Dev. 1993; 7: 2135-48.
101. Kouzarides T, Ziff E. The role of the leucine zipper in the Fos-Jun interaction. Nature 1988; 336: 646-51.
102. Rauscher FJ III, Voulalas PJ, Franza BR Jr, Curran T. Fos and Jun bind cooperatively to the AP-1 site: Reconstitution in vitro. Genes Dev. 1988; 2: 1687-99.
103. O'Shea EK, Rutkowski R, Kim PS. Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell 1992; 68: 699-708.
104. Glover JNM, Harrison SC. Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 1995; 373: 257-61.
105. Ryseck R-P, Bravo R. c-Jun, JunB, JunD differ in their binding affinities to AP-1 and CRE consensus sequences: Effect of Fos proteins. Oncogene 1991; 6: 533-42.
106. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl Acad Sci. USA 1991; 88: 3720-4.
107. Hsu W, Kerppola TK, Chen P-L, Curran T, Chen-Kiang S. Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region. Mol. Cell Biol. 1994; 14: 268-76.
108. Kataoka K, Noda M, Nishizawa M. Maf nuclear oncoprotein recognises sequences related to an AP-1 site and forms heterodimers with both Fos and Jun. Mol. Cell Biol. 1994; 14: 700-12.
109. Kerppola TK, Curran T. Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun. Oncogene 1994; 9: 675-684.
110. Jain J, McCaffrey PG, Valge-Archer VE, Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature 1992; 356: 801-4.
111. Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 1993; 12: 3879-91.
112. Li L, Chambard J-C, Karin M, Olsen EN. Fos and Jun repress transcriptional activation by myogenin and MyoD: The amino terminus of Jun can mediate repression. Genes Dev. 1992; 6: 676-89.
113. Bengal E, Ransone L, Scharffman R et al. Functional antagonism between c-Jun and MyoD proteins: A direct physical association. Cell 1992; 68: 507-19.
114. Blanar MA, Rutter WJ. Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. Science 1992; 256: 1014-18.
115. Yang-Yen H-F, Chambard J-C, Sun Y-L et al. Transcriptional interference between the c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62: 1205-15.
116. Miner J, Yamamoto KR. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev. 1992; 6: 2491-501.
117. Jain J, Valge-Archer VE, Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 1992; 148: 1240-50.
118. Gius D, Cao X, Rauscher FJ III, Cohen DR, Curran T, Sukhatme VP. Transcriptional activation and repression by Fos are independent functions: The C terminus represses immediate-early gene expression via CArG elememts. Mol. Cell. Biol. 1990; 10: 4243-55.
119. Bos TJ, Montecarlo FS, Mitsunobu F et al. Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and non-coding sequences. Genes Dev. 1990; 4: 1677-1687.
120. Schuermann M, Jooss K, Muller R. fosB is a transforming gene encoding a transcriptional activator. Oncogene 1990; 6: 567-76.
121. Muller R, Wagner EF. Differentiation of F9 teratocarcinoma stem cells after transfer of c-fos proto-oncogene. Nature 1984; 311: 438-42.
122. Sutherland JA, Cook A, Bannister AJ, Kouzarides T. Conserved motifs in Fos and Jun define a new class of activation domain. Genes Dev. 1992; 6: 1810-19.
123. Jooss KU, Funk M, Muller R. An autonomous N-terminal transactivation domain in Fos protein plays a crucial role in transformation. EMBO J. 1994; 13: 1467-75.
124. Brown HJ, Sutherland JA, Cook A, Bannister AJ. Kouzarides T. An inhibitor domain in c-Fos regulates activation domains containing the HOB1 motif. EMBO J. 1995; 14: 124-31.
125. Trainer I, Ofir R, Verma I. Alteration of a cyclic AMP-dependent protein kinase phosphorylation site in the c-Fos protein augments its transforming potential. Mol. Cell. Biol. 1992; 12: 998-1006.
126. Schonthal A, Herrlich P, Rahmsdorf HJ, Ponta H. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell 1988; 54: 325-34.
127. Braselmann S, Bergers G, Wrighton C, Graninger P, Superti-Furga G, Busslinger M. Identification of Fos target genes by the use of selective induction systems. J. Cell Sci. 1992; Suppl. 16: 97-109.
128. Wisdom R, Verma IM. Transformation by Fos proteins requires a C-terminal transactivation domain. Mol. Cell. Biol. 1993; 13: 7429-38.
129. Metz R, Kouzarides T, Bravo R. A C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is able to interact with the TATA binding protein, is required for altered cell growth. EMBO J. 1994; 13: 3832-42.
130. Metz R, Bannister AJ, Sutherland JA et al. c-Fos-induced activation of a TATA-box-containing promoter involves direct contact with the TATA-box-binding protein. Mol. Cell. Biol. 1994; 14: 6021-9.
131. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: The beginning of the end. Trends Biochem Sci. 1992; 17: 418-22.
132. Foletta VC, Sonobe MH, Suzuki T, Endo T, Iba H, Cohen DR. Cloning and characterisation of the mouse fra-2 gene. Oncogene 1994; 9: 3305-11.
133. Yoshida T, Suzuki T, Sato H, Nishina H, Iba H. Analysis of fra-2 gene expression. Nucl. Acids Res. 1993; 21: 2715-21.
134. Foletta VC. The cloning and characterisation of the mouse fra-2 gene. PhD Thesis, Australian National University, 1995.
135. Sonnenberg JL, MacGregor-Leon PF, Curran T, Morgan JI. Dynamic alterations occur in the levels and composition of transcription factor AP-1 complexes after seizure. Neuron 1989; 3: 359-65.
136. Kameda T, Akahori A, Sonobe MH, Suzuki T, Endo T, Iba H. JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2. Proc. Natl Acad. Sci. USA 1993; 90: 9369-73.
137. Suzuki T, Murakami M, Onai N et al. Analysis of AP-1 function in cellular transformation pathways. J. Virol. 1994; 68: 3527-35.
138. Sonobe MH, Yoshida T, Murakami M, Kameda T, Iba H. fra-2 promoter can respond to serum-stimulation through AP-1 complexes. Oncogene 1995; 10: 689-96.
139. Cohen DR, Sinclair AH, McGovern JD. SRY protein enhances transcription of Fos-related antigen 1 promoter constructs. Proc. Natl Acad. Sci. USA 1994; 91: 4372-6.
140. Gruda MC, Kovary K, Metz R, Bravo R. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene 1994; 9: 2537-47.
141. Muller R, Slamon DL, Tremblay JM, Cline MJ, Verma IM. Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature 1982; 299: 640-5.
142. Muller R, Verma IM, Adamson ED. Expression of c-onc genes: c-fos transcripts accumulate to high levels during development of mouse placenta, yolk sac and amnion. EMBO J. 1983; 2: 679-84.
143. Gonda T, Metcalf D. Expression of myb, myc and fos protooncogenes during the differentiation of a murine myeloid leukaemia. Nature 1984; 310: 249-51.
144. Muller R, Tremblay JM, Adamson ED, Verma IM. Tissue and cell type-specific expression of two human c-onc genes. Nature 1983; 304: 454-6.
145. Sandberg M, Vuorio T, Hirvonen H, Alitalo K, Vuorio E. Enhanced expression of TGF-β and c-fos mRNAs in the growth plates of developing human long bones. Development 1988; 102: 461-70.
146. Dony C, Gruss P. Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue. Nature 1987; 328: 711-14.
147. Smeyne RJ, Schilling K, Robertson L et al. Fos-lacZ transgenic mice: Mapping sites of gene induction in the central nervous system. Neuron 1992; 8: 13-23.
148. Smeyne RJ, Vendrell M, Hayward M et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993; 363: 166-9.
149. Gonzalez-Martin C, de Diego I, Crespo D, Fairen A. Transient c-fos expression accompanies naturally occurring cell death in the developing interhemispheric cortex of the rat. Dev. Brain Res. 1992; 68: 83-95.
150. Marti A, Jehn B, Costello E et al. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. Oncogene 1994; 9: 1213-23.
151. Redemann-Fibi B, Schuermann M, Muller R. Stage and tissue-specific expression of fosB during mouse development. Differentiation 1991; 46: 43-9.
152. Cohen DR, Vandermark SE, McGovern JD, Bradley MP. Transcriptional regulation in the testis: A role for transcription factor AP-1 complexes at various stages of spermatogenesis. Oncogene 1993; 8: 443-55.
153. Carrasco D, Bravo R. Tissue-specific expression of the fos-related transcription factor fra-2 during mouse development. Oncogene 1995; 10: 1069-79.
154. Ryder K, Nathans K. Induction of protooncogene c-jun by serum growth factors. Proc. Natl Acad. Sci. USA 1988; 85: 8464-7.
155. Wilkinson DG, Bhatt S, Ryseck R-P, Bravo R. Tissue-specific expression of c-jun and junB during organogenesis in the mouse. Development 1989; 106: 465-71.
156. Ruther U, Muller W, Sumida T, Tokuhisa T, Rajewsky K, Wagner EF. c-fos expression interferes with thymus development in transgenic mice. Cell 1988; 53: 847-56.
157. Ruther U, Garber C, Komitowski D, Muller R, Wagner EF. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 1987; 325: 412-16.
158. Ruther U, Komitowski D, Schubert FR, Wagner EF. c-fos expression induces bone tumours in transgenic mice. Oncogene 1989; 4: 861-5.
159. Grigoriadis AE, Schellander K, Wang Z-Q, Wagner EF. Osteoblasts are targets cells for transformation in c-fos transgenic mice. J Cell Biol. 1993; 122: 685-701.
160. Johnson RS, Spiegelman BM, Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992; 71: 577-86.
161. Wang Z-Q, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992; 360: 741-5.
162. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-Jun is essential for normal mouse development and hepatogenesis. Nature 1993; 365: 179-81.
163. Johnson RS, van Lingen B, Papioannou VE, Spiegelman BM. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 1993; 7: 1309-17.